Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Gilead Sciences (GILD) Q3 earnings report
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Wednesday said its third-quarter earnings increased, aided by higher revenues. The results also exceeded the market’s prediction.
Adjusted earnings increased 29% to $2.11 per share from $1.64 per share a year earlier. Analysts were looking for a smaller bottom-line number.
Net income, on an unadjusted basis, came in at $360 million or $0.29 per share, compared to a loss of $1.17 billion or $0.92 per share in the prior-year period.
Read management/analysts’ comments on Gilead Sciences Q3 earnings
Revenues moved up 17% year-over-year to $6.58 billion in the September-quarter and exceeded the market’s prediction. The company’s stock closed Wednesday’s regular trading lower, hut gained during the after-hours session.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Walgreens Boots Alliance set to report earnings next week. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with